Nina M Molenaar1,2, Eline M P Poels2, Thalia Robakis1, Richard Wesseloo2,3, Veerle Bergink1,2,4. 1. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, New York, USA. 2. Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands. 3. Department of Psychiatry, GGZ Delftland, Delft, The Netherlands. 4. Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Abstract
OBJECTIVES: Recommendations on lithium dosing around delivery vary, with several guidelines suggesting that lithium should be discontinued prior to delivery. We aimed to evaluate the validity of these recommendations by investigating 1) maternal lithium blood level changes following delivery, and 2) the association between neonatal lithium blood levels at delivery and neonatal outcomes. METHODS: In this retrospective observational cohort study, we included women with at least one lithium blood level measurement during the final week of pregnancy and the first postpartum week. For aim 2, we included a subcohort of women with neonates for whom neonatal lithium blood levels (obtained from the umbilical cord or a neonatal vein puncture within 24 hours of delivery) were available. RESULTS: There were a total of 233 maternal lithium blood level measurements; 55 (23.6%) in the week before delivery and 178 (76.4%) in the week after. There was no association between time and lithium blood level/dose ratio (Pearson correlation coefficient -0.03, P = .63). Additionally, we included a total of 29 neonates for whom a lithium measurement was performed within 24 hours postpartum. Maternal and neonatal lithium blood levels were strongly correlated. We observed no associations between neonatal lithium blood levels at delivery and neonatal outcomes. CONCLUSION: Based on our findings, we do not recommend lowering the dosage or discontinuation of lithium prior to delivery. Stable dosing can prevent subtherapeutic lithium serum levels, which is especially important in the postpartum period when relapse risks are highest.
OBJECTIVES: Recommendations on lithium dosing around delivery vary, with several guidelines suggesting that lithium should be discontinued prior to delivery. We aimed to evaluate the validity of these recommendations by investigating 1) maternal lithium blood level changes following delivery, and 2) the association between neonatal lithium blood levels at delivery and neonatal outcomes. METHODS: In this retrospective observational cohort study, we included women with at least one lithium blood level measurement during the final week of pregnancy and the first postpartum week. For aim 2, we included a subcohort of women with neonates for whom neonatal lithium blood levels (obtained from the umbilical cord or a neonatal vein puncture within 24 hours of delivery) were available. RESULTS: There were a total of 233 maternal lithium blood level measurements; 55 (23.6%) in the week before delivery and 178 (76.4%) in the week after. There was no association between time and lithium blood level/dose ratio (Pearson correlation coefficient -0.03, P = .63). Additionally, we included a total of 29 neonates for whom a lithium measurement was performed within 24 hours postpartum. Maternal and neonatal lithium blood levels were strongly correlated. We observed no associations between neonatal lithium blood levels at delivery and neonatal outcomes. CONCLUSION: Based on our findings, we do not recommend lowering the dosage or discontinuation of lithium prior to delivery. Stable dosing can prevent subtherapeutic lithium serum levels, which is especially important in the postpartum period when relapse risks are highest.
Authors: Elisabetta Patorno; Krista F Huybrechts; Brian T Bateman; Jacqueline M Cohen; Rishi J Desai; Helen Mogun; Lee S Cohen; Sonia Hernandez-Diaz Journal: N Engl J Med Date: 2017-06-08 Impact factor: 91.245
Authors: Trine Munk-Olsen; Xiaoqin Liu; Alexander Viktorin; Hilary K Brown; Arianna Di Florio; Brian M D'Onofrio; Tara Gomes; Louise M Howard; Hind Khalifeh; Holly Krohn; Henrik Larsson; Paul Lichtenstein; Clare L Taylor; Inge Van Kamp; Richard Wesseloo; Samantha Meltzer-Brody; Simone N Vigod; Veerle Bergink Journal: Lancet Psychiatry Date: 2018-06-18 Impact factor: 27.083
Authors: Richard Wesseloo; Astrid M Kamperman; Trine Munk-Olsen; Victor J M Pop; Steven A Kushner; Veerle Bergink Journal: Am J Psychiatry Date: 2015-10-30 Impact factor: 18.112
Authors: G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young Journal: J Psychopharmacol Date: 2016-03-15 Impact factor: 4.153
Authors: Melissa M Batt; Aviva K Olsavsky; Shaleah Dardar; Celeste St John-Larkin; Rachel L Johnson; Mary D Sammel Journal: Curr Psychiatry Rep Date: 2022-02-15 Impact factor: 8.081
Authors: Nina M Molenaar; Eline M P Poels; Thalia Robakis; Richard Wesseloo; Veerle Bergink Journal: Bipolar Disord Date: 2020-06-30 Impact factor: 6.744
Authors: Marlien Torfs; Titia Hompes; Michael Ceulemans; Kristel Van Calsteren; Christine Vanhole; Anne Smits Journal: Int J Environ Res Public Health Date: 2022-08-16 Impact factor: 4.614